Hemodynamic Effects of Chronic Administration of Spironolactone and/or Propranolol in Alcoholic Cirrhotic Patients
The aim of this study was assesment of splanchnic and systemic hemodynamic effects of chronic administration (2 month) of spironolactone or propranolol, alone or in association in alcoholic cirrhotic patients. The patients were randomized in 4 groups (aldactone 150 mg/day, propranolol 160 mg/day, aldactone 150 mg/day + propranolol 160 mg/day, placebo). Systemic and splanchnic hemodynamic effect were evaluated by hepatic venous pressure gradient measurements before and after 2 month of treatment.
|Study Design:||Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Primary Purpose: Prevention
|Official Title:||Hemodynamic Effects of Chronic Administration of Spironolactone, Propranolol and Their Association in Alcoholic Cirrhotic Patients|
- assessment of hepatic veinous pressure gradient changes after chronic treatment by spironolactone or propranolol alone or in association.
- Efficacy of spironolactone/propranolol association
|Study Start Date:||April 1995|
|Estimated Study Completion Date:||December 2003|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00188045
|Principal Investigator:||Paul Cales, PHD||UH Angers|